NCT05730842View on ClinicalTrials.gov

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Healthy VolunteerMuscular DystrophiesMuscular Disorders, AtrophicMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, Inborn
Interventions
DRUG

EDG-5506 Tablet

Single Oral Dose - Tablet

DRUG

Radiolabeled EDG-5506 Suspension

Single Oral Dose

DRUG

Radiolabeled EDG-5506 Intravenous

Single Intravenous Dose

Trial Locations (1)

53704

Labcorp Clinical Research Unit, Inc., Madison

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY